Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Frailty may not limit semaglutide benefits
Patients with greater frailty showed larger improvements in health-related quality of life, while cardiovascular treatment effects did not differ significantly across frailty categories.
In a SELECT trial analysis of 17,604 adults with cardiovascular disease and overweight or obesity but without diabetes, researchers assessed semaglutide outcomes by baseline frailty.
2
The primary cardiovascular outcome occurred less often with semaglutide than placebo across frailty groups, with no statistically significant interaction between frailty and treatment.
3
Semaglutide was associated with larger health-related quality-of-life improvements among patients with greater frailty, mainly in mobility, self-care, and usual activities.
4
Frailty status improved in 34% of semaglutide recipients and 18% of placebo recipients over 104 weeks, while it worsened in 10% and 19%, respectively.
5
Serious adverse events were less frequent with semaglutide, but permanent treatment discontinuation was more frequent; the exploratory findings are hypothesis-generating.
Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
